Sivik Global Healthcare LLC Makes New Investment in Novo Nordisk A/S $NVO

Sivik Global Healthcare LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, HoldingsChannel.com reports. The fund bought 75,000 shares of the company’s stock, valued at approximately $3,816,000. Novo Nordisk A/S comprises about 1.1% of Sivik Global Healthcare LLC’s holdings, making the stock its 26th biggest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. True Wealth Design LLC increased its stake in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the last quarter. Guerra Advisors Inc acquired a new stake in Novo Nordisk A/S during the third quarter worth $25,000. American National Bank & Trust acquired a new stake in Novo Nordisk A/S during the fourth quarter worth $28,000. Strengthening Families & Communities LLC acquired a new stake in Novo Nordisk A/S during the third quarter worth $30,000. Finally, Allianz SE increased its stake in Novo Nordisk A/S by 70.0% during the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after acquiring an additional 238 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. The Goldman Sachs Group reissued a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. HSBC reaffirmed a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Up 0.6%

Shares of NVO opened at $36.91 on Wednesday. The stock has a market capitalization of $164.78 billion, a PE ratio of 10.64, a P/E/G ratio of 8.75 and a beta of 0.73. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company’s 50-day simple moving average is $42.36 and its 200-day simple moving average is $49.38.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 50.14%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Launch of higher‑dose Wegovy (Wegovy HD) in the U.S. — Novo made a 7.2 mg Wegovy injection available nationwide, which should boost per‑patient efficacy and help recover market share and pricing momentum in obesity treatments. Novo Nordisk launches higher-dose Wegovy in the United States
• Positive Sentiment: Oral Wegovy pill driving new patient demand — Reports indicate the Wegovy pill rollout is bringing new patients into GLP‑1 treatment rather than merely converting injectable users, expanding addressable market and supporting longer‑term revenue growth. Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
• Positive Sentiment: Share repurchase programme — Novo continues executing a buyback (part of up to DKK 15bn over 12 months), which supports EPS and signals balance‑sheet confidence. Novo Nordisk A/S – Share repurchase programme
• Neutral Sentiment: Company messaging that the weight‑loss boom is “just beginning” — Management’s optimistic outlook supports growth expectations but may already be priced in. Novo Says Weight-Loss Boom Is Just Beginning
• Neutral Sentiment: Valuation and volatility analysis — Recent share moves have prompted fresh valuation reviews noting size and revenue scale; these analyses can temper investor enthusiasm if multiples look stretched. Assessing Novo Nordisk (CPSE:NOVO B) Valuation After Recent Share Price Volatility
• Negative Sentiment: Rival approvals and competition — Eli Lilly and others advancing oral obesity pills (e.g., Foundayo) increase competitive pressure on pricing and market share over time. How to Play Lilly Stock Post Oral Obesity Pill Foundayo’s Approval
• Negative Sentiment: Analyst downgrade citing GLP‑1 pipeline risks — At least one sell‑side critique highlights pipeline and execution risks that could weigh on the stock if clinical or regulatory setbacks emerge. Novo Nordisk: Downgrading To ‘Sell’ As GLP-1 Pipeline Faces Many Risks

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.